Akiram Therapeutics is a science-driven company that focuses on advancing radiotherapeutics to treat solid tumors. They specialize in the development of next-generation radiopharmaceuticals that are designed to specifically and efficiently visualize and treat solid cancers. Their innovative approach involves the use of systemic targeted radiopharmaceuticals, which can selectively deliver radioisotopes to tumors via the bloodstream, ultimately accumulating in the tumor tissue. This accumulation of radioactivity enables the visualization and potential eradication of the cancer tissue.

One of Akiram Therapeutics' notable accomplishments is the development of a new type of targeted radioimmunotherapy. This ground-breaking treatment has shown promising results in several studies and has the potential to become a first-in-class therapy. Animal studies have demonstrated a 100% survival rate and complete disappearance of tumors with just one treatment. This targeted radioimmunotherapy approach is poised to become the next big breakthrough in cancer treatment and has garnered significant interest from big pharma.

Akiram Therapeutics has also successfully developed a unique antibody that guides radiation to the tumor while sparing surrounding tissues. This antibody has undergone extensive research and testing, resulting in its ability to bind strongly only to cancer tumors and selectively radiate them, leaving other tissues unaffected.

With a team of experienced founders and ongoing developments in the field of cancer treatment, Akiram Therapeutics is at the forefront of advancing radiotherapeutics for the benefit of patients worldwide.